SCHEMBL7413469

SCHEMBL7413469

O=C1COCc2ncccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.41
NSD2 O96028 1/20 0.41
ABL1 P00519 1/20 0.41
PLCG1 P19174 1/20 0.41
CES1 P23141 1/20 0.41
PAX8 Q06710 1/20 0.41
RIN1 Q13671 1/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 1/20 0.41
CDC25B P30305 3/20 0.37
PTPRC P08575 2/20 0.37
S100A4 P26447 2/20 0.37
CTSL P07711 1/20 0.37
CTSS P25774 1/20 0.37
PTPN13 Q12923 1/20 0.37
MAPK14 Q16539 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31064536 1.00 TDP2 (0.41) TDP2NSD2ABL1PLCG1CES1
SCHEMBL905642 0.76 MAOB (0.47) TDP2NSD2ABL1PLCG1CES1
SCHEMBL29361803 0.76 MAOB (0.47) TDP2NSD2ABL1PLCG1CES1
SCHEMBL936485 0.74 MAOA (0.48) TDP2NSD2ABL1PLCG1CES1
SCHEMBL29807425 0.74 TDP2 (0.45) TDP2NSD2ABL1PLCG1CES1
SCHEMBL4015467 0.74 TDP2 (0.45) TDP2NSD2ABL1PLCG1CES1
SCHEMBL10146421 0.73
SCHEMBL31069046 0.73
SCHEMBL3294825 0.71 TDP1 (0.42) TDP2NSD2ABL1PLCG1CES1
SCHEMBL8327818 0.71 GRM5 (0.44) TDP2NSD2ABL1PLCG1CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124442-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS AMGEN INC. (US) 2024-04-18 US disclosed
EP-4288435-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS Amgen Inc. (US) 2023-12-13 EP disclosed
CN-117062816-A Tricyclic-amide-bicyclic PRMT5 inhibitors 美国安进公司 2023-11-14 CN disclosed
WO-2022169948-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS AMGEN INC. (US) 2022-08-11 WO disclosed
WO-2015173035-A1 HERBICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2015-11-19 WO disclosed
EP-0770078-A1 8-ARYL-1,6-NAPHTHYRIDIN-5-ONES F. HOFFMANN-LA ROCHE AG (CH) 1997-05-02 EP disclosed
WO-1996002541-A1 8-ARYL-1,6-NAPHTHYRIDIN-5-ONES F. HOFFMANN-LA ROCHE AG (CH) 1996-02-01 WO disclosed
US-5466697-A 8-phenyl-1,6-naphthyridin-5-ones SYNTEX (U.S.A.) INC. (US) 1995-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124442-A1 TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 TDP2 1612/4885NSD2 244/4885ABL1 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.